Skip to main content

Table 2 Pharmacokinetic parameters of two doses administered SC in 10 New Zealand White Rabbits

From: Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits

PK parameter Sex SC 0.05 [mean ± SD (range)] SC 0.1 [mean ± SD (range)]
AUC0-t (ng/mL/min) F 423 ± 149 (285–665) 633 ± 211 (362–863)*
M 366 ± 178 (254–632) 958 ± 387 (470–1357)***
AUC0-∞ (ng/mL/min) F 634 ± 204 (381–890) 1207 ± 261 (961–1572)***
M 439 ± 180 (332708) 1093 ± 388 (559–1501)***
Cmax (ng/mL) F 2.6 ± 1.7 (1.0–5.2) 2.5 ± 0.6 (1.8–3.3)
M 1.6 ± 0.8 (0.8–2.7) 7.0 ± 3.4 (3.3–11.5)**
Bioavailability (%) F 48 ± 21 (26–81) 36 ± 14 (20–58)
M 53 ± 22 (35–82) 71 ± 23 (43–94)**
t½
(min)
F 315 ± 139 (156–495) 444 ± 185 (305–717)
M 192 ± 38 (138–218) 162 ± 31 (130–201)
tmax
(min)
F 12 ± 11 (5–30) 14 ± 10 (5–30)
M 73 ± 81 (5–180) 12 ± 11 (5–30)*
  1. SC subcutaneous, AUC0-t area under the concentration curve from t0 to t480min, AUC0-∞ area under the concentration curve from t0 to infinity, Cmax maximum concentration, Bioavailability AUC0-t IM or SC / AUC0-t IV, t½ elimination half-life, tmax time at maximum concentration. (*p < 0.05, **p < 0.01. ***p < 0.001 two-way ANOVA with route and sex as independent factors, and animal and treatment day as blocking factors, followed by comparison between the SC 0.05 mg/kg and SC 0.1 mg/kg groups)